search
Back to results

The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial (VIGOR)

Primary Purpose

Type 1 Diabetes

Status
Terminated
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Exercise Training
Sponsored by
University of Manitoba
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Type 1 Diabetes focused on measuring Type 1 Diabetes, Hypoglycaemia, Glycaemic variability, Vigorous Intensity Physical Activity, Continuous Glucose Monitoring

Eligibility Criteria

15 Years - 45 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age: 15-45 years old
  • Have lived with type 1 diabetes for at least 2 years
  • HbA1c <9.9%
  • Currently physically inactive (<150 minutes of self-reported structured physical activity per week)
  • Undergone a resting ECG to screen for left ventricular hypertrophy, arrhythmias or signs or coronary artery disease that may be exacerbated with vigorous intensity exercise

Exclusion Criteria:

  • Have frequent and unpredictable hypoglycaemia
  • Had a change in insulin management strategy, including adoption of a pump, within 2 months of enrolment
  • Are currently participating in structured activity or sport-related activities
  • Are women who are pregnant or planning to get pregnant within the 12 months of the trial and those who are breastfeeding
  • Have conditions that would render physical activity contraindicated including: uncontrolled hypertension (BP>150mmHg systolic or >95mmHg diastolic in a sitting position); severe peripheral neuropathy; history of cardiovascular disease
  • Have a cognitive deficit resulting in an inability to provide informed consent
  • Currently taking beta blockers
  • Currently taking atypical antipsychotics or corticosteroids

Sites / Locations

  • University of Calgary
  • University of Alberta
  • Manitoba Institute of Child Health
  • McMaster University
  • University of Ottawa

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Moderate intensity exercise

Moderate + Vigorous Intensity Exercise

Arm Description

150-200 minutes of weekly moderate intensity exercise (45-55% of peak fitness)

150-200 minutes of weekly moderate intensity exercise, with short bouts of vigorous intensity exercise (80-90% of peak fitness)

Outcomes

Primary Outcome Measures

Time Spent in Hypoglycaemia in the 12-hour Period Following Exercise, Defined as an Interstitial Glucose Reading <4.0mmol/L and Measured by Continuous Glucose Monitor.

Secondary Outcome Measures

Glycaemic Variability, Measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour Period Following Exercise. This is Calculated From the Same Continuous Glucose Monitor Data as the Primary Outcome.

Full Information

First Posted
March 27, 2013
Last Updated
January 16, 2018
Sponsor
University of Manitoba
Collaborators
Manitoba Institute of Child Health
search

1. Study Identification

Unique Protocol Identification Number
NCT01834144
Brief Title
The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial
Acronym
VIGOR
Official Title
The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Terminated
Why Stopped
Funding for the study was not renewed
Study Start Date
May 2013 (undefined)
Primary Completion Date
June 15, 2015 (Actual)
Study Completion Date
June 15, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Manitoba
Collaborators
Manitoba Institute of Child Health

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background/Justification: Regular physical activity (PA) has substantial health benefits in persons with type 1 diabetes (T1D), including reduced risk of complications and cardiovascular mortality. Despite these benefits, individuals with T1D remain significantly less active than their peers without diabetes. Two major factors likely explain the low rates of PA in young people with T1D: (1) fear of post-exercise hypoglycaemia, particularly nocturnal hypoglycaemia, and (2) a lack of empirical evidence for the efficacy of PA for achieving optimal glycaemic control. A number of acute exercise trials recently demonstrated that the inclusion of vigorous intensity PA in conventional moderate intensity (i.e. walking) PA sessions may overcome these limitations. No studies have tested the efficacy of high intensity PA for reducing the risk of exercise-related hypoglycaemia or glycaemic variability in a randomized controlled trial (RCT). Study Hypotheses: In persons 15-35 years of age living with T1D, this study will test the hypotheses that (1) the addition of intermittent vigorous intensity PA to a moderate intensity intervention will reduce the time spent in hypoglycaemia in the 12 hour period following exercise and (2) the addition of intermittent vigorous intensity PA to a moderate intensity PA intervention will elicit significant improvements in glycemic excursions, as measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour period following exercise.We are also exploring the hypothesis that reducing the risk of hypoglycemia will lead to a sustained increase in physical activity one year after randomization.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes
Keywords
Type 1 Diabetes, Hypoglycaemia, Glycaemic variability, Vigorous Intensity Physical Activity, Continuous Glucose Monitoring

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Moderate intensity exercise
Arm Type
Active Comparator
Arm Description
150-200 minutes of weekly moderate intensity exercise (45-55% of peak fitness)
Arm Title
Moderate + Vigorous Intensity Exercise
Arm Type
Active Comparator
Arm Description
150-200 minutes of weekly moderate intensity exercise, with short bouts of vigorous intensity exercise (80-90% of peak fitness)
Intervention Type
Other
Intervention Name(s)
Exercise Training
Primary Outcome Measure Information:
Title
Time Spent in Hypoglycaemia in the 12-hour Period Following Exercise, Defined as an Interstitial Glucose Reading <4.0mmol/L and Measured by Continuous Glucose Monitor.
Time Frame
Measured at baseline, and 1, 8,16 and 52 weeks following randomization
Secondary Outcome Measure Information:
Title
Glycaemic Variability, Measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour Period Following Exercise. This is Calculated From the Same Continuous Glucose Monitor Data as the Primary Outcome.
Time Frame
Measured at baseline, and 1, 8, 16 and 52 weeks following randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age: 15-45 years old Have lived with type 1 diabetes for at least 2 years HbA1c <9.9% Currently physically inactive (<150 minutes of self-reported structured physical activity per week) Undergone a resting ECG to screen for left ventricular hypertrophy, arrhythmias or signs or coronary artery disease that may be exacerbated with vigorous intensity exercise Exclusion Criteria: Have frequent and unpredictable hypoglycaemia Had a change in insulin management strategy, including adoption of a pump, within 2 months of enrolment Are currently participating in structured activity or sport-related activities Are women who are pregnant or planning to get pregnant within the 12 months of the trial and those who are breastfeeding Have conditions that would render physical activity contraindicated including: uncontrolled hypertension (BP>150mmHg systolic or >95mmHg diastolic in a sitting position); severe peripheral neuropathy; history of cardiovascular disease Have a cognitive deficit resulting in an inability to provide informed consent Currently taking beta blockers Currently taking atypical antipsychotics or corticosteroids
Facility Information:
Facility Name
University of Calgary
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 1N4
Country
Canada
Facility Name
University of Alberta
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2R3
Country
Canada
Facility Name
Manitoba Institute of Child Health
City
WInnipeg
State/Province
Manitoba
ZIP/Postal Code
R3E 3P4
Country
Canada
Facility Name
McMaster University
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8S 4L8
Country
Canada
Facility Name
University of Ottawa
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1N 6N5
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial

We'll reach out to this number within 24 hrs